The Food and Drug Administration (FDA) has granted traditional approval to Imdelltra ® (tarlatamab-dlle) for the treatment of adults with extensive stage small cell lung cancer (ES-SCLC) with disease ...
Most lung cancer in the U.S. is diagnosed at Stage 4, after the leading cause of cancer deaths has spread to other parts of the body. However, a Maryland health system is outpacing national averages ...
In my first 25 years at WTOP, my reports about lung cancer were primarily stories about famous people who died from the deadliest and second-most common cancer in the U.S. — until I was diagnosed with ...
Tarlatamab-dlle significantly improves overall survival in SCLC compared to standard chemotherapy, as demonstrated in the phase 3 DeLLphi-304 trial. The bispecific T-cell engager targets DLL3 on tumor ...
As Tania Rodrigues drove to work one morning in January 2024, something unusual happened with her vision. “All of a sudden, I was looking through a kaleidoscope or perhaps like a fly’s eye,” the ...
Amgen has detailed a positive phase 3 readout for its T-cell engager Imdelltra in previously treated small cell lung cancer (SCLC). The DLL3xCD3 bispecific has shown that it can help patients live ...
Lung cancer treatment has been evolving rapidly, with newer therapies increasingly tailored to specific genetic mutations — a phenomenon known as precise oncology. Among these developments is ...
As Tania Rodrigues drove to work one morning in January 2024, something unusual happened with her vision. “All of a sudden, I was looking through a kaleidoscope or perhaps like a fly’s eye,” the ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback